David Reese, MD
Medical Oncologist
Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Photodynamic Therapy Targeted Therapy
University of Cincinnati College of Medicine
Medical School
American Board of Internal Medicine - Oncology
CA State Medical License: 1991 - 2016
Amgen
Languages: English/Spanish
(805) 447-1000
1 Amgen Center Dr
Thousand Oaks, California 91320
Phase Ib study of recombinant human (rh)Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients (pts) with advanced non-small cell l...
Soria J, Smit EF, Khayat D, Besse B, Burton J, Yang X, Hsu M, Braun A, Reese D, Blackhall F; J. Clin. Oncol.. 2008-05-20.
See more >>Phase II study of docetaxel (D) plus bevacizumab (B) in Her/2 negative metastatic breast carcinoma (MBC).
Chan D, Allen H, Hu E, Reese D, Patel G, Gottlieb C, Wax A, Sosa J, Slamon D, Kabbinavar F; J. Clin. Oncol.. 2006-06-20.
See more >>HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz, J., Reese, D.M., Lindsay, M., Riva, A.; Clin Breast Cancer. 2002 Oct.
See more >>